Polygon Labs released Bor v2.10.3 to address two medium-severity denial-of-service vulnerabilities in BlockSTM V2 that caused delays and memory issues during block processing. The flaws could delay block imports by about 11 seconds and cause nodes to allocate excessive memory, potentially making nodes fall behind. The update caps cache sizes and reuses code hashes to prevent these issues without affecting transaction outcomes or consensus. The patch was rolled out privately before the public release, requires no hard fork, and operators are urged to upgrade promptly.
Polygon Labs' Bor v2.10.3 update addresses BlockSTM flaws. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 16, 2026 16:31 WIB: out of 50 major cryptocurrencies, 45 rose and 4 fell. ZIL dropped 15.40% to Rp48 with 100% buy orders and a typical hold time of 133 days, contrasting with BAT's 12.87% rise to Rp3,552 despite 87% sell orders and a 93-day hold time. BAL gained 11.14% to Rp16,297 with an 85-day typical hold time.
NeOnc Technologies reported early clinical improvement in a critically ill three-year-old boy with an aggressive brain tumor treated with investigational intranasal NEO100 under compassionate use in Abu Dhabi. The child is now breathing independently...
TransUnion's Branded Call Display, a solution that helps consumers identify legitimate callers and avoid robocall fraud, has been named one of TIME's Best Inventions of 2026 in the Connectivity & Communication category. The technology displays a busi...
La Rosa Holdings Corp. will change its name to Stratum Holdings Corp. on October 19, 2026, reflecting its shift from real estate services to an AI infrastructure company specializing in GPU leasing and high-performance computing. The company recently...
ASUS has released the ProArt P16 and P14 laptops in Canada, powered by NVIDIA RTX Spark technology. These laptops feature up to 128GB of unified memory and advanced AI capabilities designed for creators, AI developers, and workflow builders, enabling...
OXB, a global cell and gene therapy CDMO, has appointed Dr Joachim Kreuzburg as an Independent Non-Executive Director effective November 23, 2026. Dr Kreuzburg brings over 20 years of leadership in life sciences, notably transforming Sartorius AG int...
